Eph receptors and ephrins as targets for cancer therapy

Hong-Qing Xi #, Xiao-Song Wu #, Bo Wei, Lin Chen *

Department of General Surgery, Chinese People’s Liberation Army General Hospital, Beijing, China

Received: April 4, 2012; Accepted: July 13, 2012

Abstract

Eph receptor tyrosine kinases and their ephrin ligands are involved in various signalling pathways and mediate critical steps of a wide variety of physiological and pathological processes. Increasing experimental evidence demonstrates that both Eph receptor and ephrin ligands are overexpressed in a number of human tumours, and are associated with tumour growth, invasiveness and metastasis. In this regard, the Eph/ephrin system provides the foundation for potentially exciting new targets for anticancer therapies for Eph-expressing tumours. The purpose of this review is to outline current advances in the role of Eph receptors and ephrin ligands in cancer, and to discuss novel therapeutic approaches of anticancer therapies.

Keywords: Eph receptor ● Ephrin ● therapeutic target

Introduction

Eph receptors (Ephs) are the largest subfamily of receptor tyrosine kinases (RTKs) [1, 2], with 16 members cloned [3]. They are divided into two groups, EphA and EphB, depending on the types of ligands (ephrins) that they bind [4]. Since the first Eph gene was cloned in 1987 [5], the first ephrin ligand was also identified from cancer cells a few years later [6, 7]. Interactions between Ephs and the appropriate ephrin ligand activate bidirectional signalling and transducer signalling cascades. Eph receptors and ephrin ligands play critical roles in various biological functions, such as embryonic patterning, development of the nervous system and angiogenesis. However, deregulated activation of Eph/ephrin signalling in humans is thought to lead to tumorigenesis [8]. A number of studies have demonstrated overexpression of Ephs and ephrins in a variety of human tumours including melanoma [9–11], neuroblastoma [12], malignant glioma [13, 14] and carcinoma of the pancreas [15], breast [16–18], colon [19, 20], prostate [21, 22], lung [23], gastrointestinal tract [24, 25], ovaries [26, 27], oesophagus [28], liver [29, 30] and thyroid [31]. The up-regulation of Ephs and ephrins in human cancer is associated with poor prognosis and high vascularity in cancer, suggesting a detrimental role for the Eph/ephrin system in tumour progression [32]. In addition, it has been suggested that up-regulated Eph expression levels could
be used as molecular markers for the diagnosis of invasive and metastatic tumours [17]. However, not only up-regulation but also down-regulation of Ephs and ephrins have been associated with tumour progression, and both Eph receptors and ephrin ligands can promote or suppress tumour growth. Eph receptors and ephrin ligands that are preferentially expressed in extremely invasive and metastatic tumours have provided the foundation for potentially exciting new targets for anticancer therapies for these tumours. To date, numerous strategies targeting the Eph/ephrin family have been developed for cancer treatment. This review describes the structure of Eph receptors and ephrin ligands and their signalling pathway, and summarizes the roles of Ephs/ephrins in cancer and anticancer therapies.

Structure of Eph receptors and ephrin ligands

Ephs are divided into two subclasses, EphA (EphA1-10) and EphB kinases (EphB1-6), on the basis of the sequence homology and the means by which they interact with membrane-anchored ephrin ligands. Both EphA and EphB receptors contain a single transmembrane-spanning domain. The extracellular region of Eph receptors is glycosylated, and contains a ligand-binding domain, a cysteine-rich domain and two fibronectin type III repeats. The intracellular region contains a juxtamembrane region with several conserved tyrosine residues, a tyrosine kinase domain, a sterile α motif (SAM) domain and a PDZ-binding motif within the non-catalytic region of the COOH-terminus [33, 34]. On the basis of their structural features and binding specificity to EphA and EphB receptors, ephrins are also divided into two subclasses, ephrinA and ephrinB. EphrinA (A1-A6) ligands are tethered to the extracellular cell membrane via a glycosylphosphatidylinositol (GPI) anchor, whereas ephrinB (B1-B3) ligands are transmembrane proteins that possess a short cytoplasmic region with a PDZ-binding motif. EphA receptors typically bind to ephrinA ligands, and EphB receptors bind to ephrinB ligands. However, this does not preclude cross-binding, as has been shown for EphA4, which can bind to ephrinA and ephrinB ligands, and EphB2 which can bind to ephrinA5 [35–37] (Fig. 1A).

Interaction between Eph receptors and their ephrin ligands

Specificity of the binding of ephrins to their Ephs is mediated by the N-terminal glycosylated ligand-binding domain of Ephs [38]. Eph receptors and ephrins expressed in opposing cells interact in trans form and activate bidirectional signalling. (Fig. 1B). Eph receptors and ephrins coexpressed in the same cell interact in cis form [39]. Cis interaction has been shown to inhibit trans interaction and/or signalling [40, 41]. Upon binding, the Eph/ephrin molecules form heterotetramers to initiate the signal. As a rule, on ephrin binding, Eph clustering leads to activation of the tyrosine kinase domain, resulting in autophosphorylation of certain intracellular tyrosine residues [42].
Eph signalling can also occur [43, 44]. For example, EphA8 receptor results in mitogen-activated protein kinase (MAPK) activation in a neural cell line [45], and promotes integrin-mediated cell attachment in a tyrosine kinase activity-independent fashion [46]. A previous study has also indicated that EphB4 can affect cancer cell behaviour in an ephrin-independent manner [47].

Bidirectional signalling

Bidirectional signalling is an important feature of Eph-ephrin signalling and arises due to activation of signalling pathways in both the receptor-expression and the ligand-expression cells [48]. Forward and reverse signalling are activated by Ephs and ephrins respectively [39] (Fig. 2).

Forward signalling

Eph receptors can regulate biological effects through different kinase-mediated forward signalling molecules and pathways, including small GTPases of Rho members (Rho, Rac and Cdc42), focal adhesion kinase (FAK), the PI3 kinase pathway and Jak/Stat pathway [49, 50]. Small GTPases of the Rho family, which are activated by Eph receptors, control cell shape and movement by promoting the formation of stress fibres (Rho), lamellipodia (Rac) and filopodia (Cdc42) [51, 52]. The EphA receptor activates GTPases through the exchange factor, ephexin. Ephexin, which is preferentially expressed in the nervous system, binds the kinase domain of EphA. EphrinA-induced signals initiate growth cone collapse through the activation of Rho and its downstream effectors [52]. In melanoma and 293T cells, ephrinA-induced recruitment of Crk to EphA3 and a rapid, transient increase in activated Rho causes the retraction of cell processes, cell rounding and membrane blebbing. In addition, SH3 mutant Crk ablates Rho activation and ephrinA-induced cell morphological changes [53]. EphB receptors appear to associate with the exchange factors intersectin [54] and kalirin [55]. Intersectin could activate the Rho-family GTPase Cdc42 and its activity is enhanced by EphB receptor. Activation of the EphB receptor induces translocation of kalirin, an exchange factor for Rac, to synapses and leads to increased local Rac1 activation. The EphB-intersectin-Cdc42 and EphB-kalirin-Rac pathways have been proposed to regulate the EphB-receptor-mediated cytoskeletal reorganization, mesenchymal invasion and migration [54, 55]. Ephs also regulate the activity of small GTPases of the Ras family, including H-Ras and R-Ras [56, 57]. H-Ras can in turn activate a MAPK pathway that is very important for transcriptional regulation, cell proliferation, cell migration, neurite outgrowth and axon guidance [58, 59]. Activation of Eph receptors negatively regulates the Ras-MAPK pathway in various cell types [57, 60–62]. For example, activation of EphA2 could down-regulate the Ras-MAPK pathway in fibroblasts, epithelial cells, endothelial cells and tumour cells [57]. EphB2 transiently down-regulates H-Ras activity and MAPK phosphorylation and leads to neurite retraction in the NG108 neuronal cell line [60, 63]. Eph receptor-mediated activation of R-Ras also suppresses the MAPK pathway. EphB activation can reduce integrin-mediated adhesion via negative regulation of the R-Ras-MAPK pathway [56]. Focal adhesion kinase, which is a critical component of integrin signalling, may connect Eph receptors with integrins [49]. In PC-3 prostate cancer cells, ligand activation of EphA2 causes dissociation of FAK. EphB2-regulated cell positioning via PI3K, independently of kinase activity, because of this, PI3K activity is important for conveying positional information [64]. In contrast, EphB signalling could drive cell proliferation by promoting cell cycle entry. Cylcin D1 is a regulator of cell cycle entry [65]. In Genander’s study, EphB2 activity drove cells proliferation through Abl, resulting in post-transcriptional regulation of cylcin D1 protein levels [64]. In breast cancer cells, Abl binds to EphB4 in an activity-dependent manner. EphB4 activates an anti-oncogenic pathway involving Abl family tyrosine kinases and the Crk adaptor protein. This Abl-Crk pathway inhibits breast cancer cell viability and proliferation in addition to motility and invasion [66]. Autophosphorylation of EphA4 could lead to the activation of Jak2, which in turn phosphorylated Stat1 and Stat3, and promoted transcriptional activity and cells proliferation [50]. Taken together, Jak/Stat proteins were considered to be downstream targets of EphA4 signalling.

Reverse signalling

The interaction between Ephs receptors and their ephrins not only induces forward signalling by the Eph receptor but also leads to reverse signalling by the ephrin ligand [67]. EphrinA ligands can transmit signals despite lacking a cytoplasmic domain. The mechanisms of reverse signalling of ephrinA ligands are thought to be associated with ephrinA clustering and recruitment of regulatory proteins [68]. EphrinA ligands are anchored to the membrane by covalent linkage to GPI, and depend on transmembrane coreceptors for transmitting signals intracellularly [69]. It has been shown that signalling through ephrinA ligands is mediated by the recruitment of adapter proteins. The ephrinA ligands are targeted to lipid rafts, which contain some signalling molecules such as cavinin proteins and G proteins. This indicates that ephrinA ligands may activate a number of signalling pathways [70]. Src-family tyrosine kinases are important regulators of signalling through GPI-anchored proteins [71, 72]. Davy et al. [68] demonstrated that activation of Src kinase family members is important for signalling downstream of ephrinA5. Interaction of ephrinA5 with EphA-Fc fusion proteins has been shown to recruit and activate the Src-family kinase, Fyn. Subsequently, Fyn was shown to increase tyrosine phosphorylation of p80, and induce a change in the cellular architecture and adhesion of the ephrinA5-expressing cells. Bonanomi et al. [69] showed that Ret, which is also a RTK, is required for motor axon attraction mediated by ephrinA reverse signalling. Because of this, Ret is a transmembrane coreceptor and is dependent on ephrinA ligand for transmitting signals. Recent data demonstrate that activation of ephrinA2 and ephrinA5 by EphA3 leads to a p11-integrin-dependent increase in the adhesion of ephrinA-expressing cells to laminin [73]. This may be because of p120 (120-kDa raft membrane protein), which plays a role in coupling ephrinA activation to integrin activation. Blocking the p120 can abolish the increase in cell adhesion. EphiinA5 engagement activates
MAPK, through both integrin-dependent and integrin-independent pathways, which in turn regulate cell architecture and morphology [74]. These studies indicate that ephrinA can influence cellular biological behaviour by transducing signals. EphrinB ligands are similar to Ephs in that they contain a single transmembrane domain, a cytoplasmic region and a PDZ-binding motif. EphrinB reverse signalling also involves Src kinases family that are responsible for ephrinB phosphorylation following Eph receptor binding [48, 67, 75, 76]. Phosphorylated ephrinB can initiate reverse signalling through SH2 or PDZ-domain-containing proteins [77, 78]. The adaptor protein, Grb4, contains an SH2 domain and can link ephrinB ligands to a signalling network that modifies cell morphology [77]. The GTPase-activating protein PDZ-RGS3 binds to the cytoplasmic C terminus of ephrinB through its PDZ domain. PDZ-RGS3 can mediate signalling that is induced by ephrinB1 [78]. EphrinB also plays significant roles in boundary formation. In Zebrafish embryo studies, bidirectional signalling between ephrinB2 and EphB2 at rhombomere boundaries restricts cell intermingling [79]. Loss of the ephrinB2 cytoplasmic domain in mice results in defects in vasculogenesis and angiogenesis, which are very similar to those observed in ephrinB2-knockout mice [80]. EphrinB signalling was also shown to play critical roles in vascular development by a corneal micropocket assay [81]. Therefore, this suggests that reverse signalling is required for vascular development of vasculature.

Fig. 2 EphA/ephrinA bidirectional signalling. (A) Stimulation of ephrinA5 recruits and activates the Src-family kinase, FYN. Subsequently, FYN induces a change in the cellular architecture and adhesion of ephrinA5-expressing cells [68] and results in mitogen-activated protein kinase (MAPK) activation [74]. (B) EphA4 activates signal transducers and STAT3 [50]. EphA receptors directly activate GTPases of the Rho family (RHOA, RAC1 and CDC42) through the exchange factor Ephexin [51, 52]. This pathway involves EphA2 and PI3 kinase in endothelial cells [151]. EphA2 inhibits Akt [190, 191] and inactivates focal adhesion kinase (FAK) through the SHP2 phosphatase [48]. EphA2 activates RHOA through FAK [192, 193]. EphA1 inhibits integrin-linked kinase (ILK) [194]. EphB/ephrinB bidirectional signalling. (C) Growth Factor Receptor Bound protein 4 (GRB4) contains a SH2 domain and can link ephrinB ligands to a signalling network that modifies cell morphology [77]. EphrinB1 disrupts focal adhesions through GRB4 [48]. The phosphatase PTP-PL is recruited to the ephrinB carboxy-terminal tail. PTP-PL dephosphorylates ephrinB and inactivates Src [35]. PDZ-RGS3 binds constitutively to ephrinB and catalyses the hydrolysis of GTP to GDP in the G-Alpha subunit of heterotrimeric GPCR. It also inhibits SDF1-mediated cell chemotaxis through the CXCR4 [195]. (D) EphB forward signalling activates RAC1 and CDC42 exchange factors [48, 146, 193]. EphB2 activates Ras GAP to inhibit the H-RAS and R-RAS [48, 196]. EphB2 regulates cell positioning via PI3K [64]. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway [66]. EphB2 regulates cell proliferation through an Abl-cyclin D1 pathway [64].
Ephs and ephrins in developing and adult tissues

The Eph/ephrin system is associated with various signalling pathways, and participates in diverse biological processes such as cell proliferation and viability, cytoskeletal organization, cell migration and embryonic development. It plays key roles in the development of the nervous system, for example, in axon guidance [82], axon fascilitation [83] and neural crest cells migration [84]. EphB receptors and ephrinB ligands regulate synaptogenesis, including the establishment and modification of the post-synaptic specialization [85, 86]. Eph/ephrin signalling is also essential for formation of villi and crypts in the intestinal epithelium [87].

Most Eph receptors and ephrin ligands are not only expressed during development but are also expressed in adult tissues [88]. Hafner et al. [19] investigated the expression of 12 Eph receptors (EphA1–A8 and EphB1–B6) and 8 ephrin ligands (ephrinA1–A5 and ephrinB1–B3) in 13 different type of healthy human tissue, including brain, lung, liver, spleen, colon, small intestine, kidney, bladder, prostate, testis, uterus, thymus and bone marrow. They reported that except for EphA8 and ephrinA2, all members of the family were expressed in all investigated normal tissues. However, Eph and ephrin proteins are expressed at much lower levels in adult compared with embryonic tissue [89]. Some articles demonstrate that low-level expression of Eph and ephrin in the adult gut [87], vasculature [90] and kidney [91], and could continue play a role in tissue architecture. In contrast, the high-level expression of Eph and ephrin proteins has been studied in very few normal tissues. For example, the expression of Eph and ephrin is relatively strong in the brain, where Eph may participate in the processes of synaptic plasticity, learning and memory [92].

Ephs and ephrins in cancer

It is generally recognized that Eph receptors and ephrin ligands play considerable roles in carcinogenesis, cancer progression and neovascularization of various human malignancies. The expression of Eph receptors and ephrin ligands has been identified in multiple types of human tumours, including melanoma [9–11], neuroblastoma [12], malignant glioma [13, 14] and carcinoma of the pancreas [15], breast [16–18, 74], colon [19, 20], prostate [21, 22], lung [23], gastrointestinal tract [24, 25], ovaries [26, 27], oesophagus [28], liver [29, 30] and thyroid [31]. The expression of Ephs and ephrins is often correlated with tumour malignancy by interacting with both ErbB2 and epidermal growth factor receptor (EGFR) [97, 98]. Hypermethylated in cancer 1 (HIC1), a tumour suppressor gene, encodes a transcriptional repressor that is silenced in many human tumours. Recent research on breast cancer identified EphA2 as a direct target gene of HIC1. Infection of breast cancer cell lines with a retrovirus expressing HIC1 was shown to reduce EphA2 mRNA and protein [99]. Thus, deregulation of the EphA2 pathway by silencing HIC1 might play an important role in the progression of breast cancer.

EphB4 provides a survival advantage in breast cancer by attenuating the inherent cell death pathways and up-regulating antiapoptotic proteins. EphB4 knockdown has been found to inhibit breast cancer cell viability, migration and invasion in vitro and tumour growth in vivo [100]. Furthermore, EphB4 receptor signalling is also able to suppress breast tumour cell growth and motility [66]. Recently, a retrospective study demonstrated that EphA2, EphA4, EphA7, EphB4 and EphB6 were significantly correlated with poor prognosis of breast cancer patients [101]. This suggests that these Eph family members may become useful targets for therapeutic intervention and potential indicators for clinical assessment of tumour prognosis.

Colorectal cancer

Several studies have identified a role for Ephs and ephrins in colorectal cancer. A recent study demonstrated significant up-regulation of EphA1 in over 50% of colorectal cancer cases (P = 0.005), whereas many of the remaining patients showed down-regulation of EphA1 [102]. In addition, EphA1 overexpression was more in stage II compared to stage III colorectal cancer. Low EphA1 expression has been significantly correlated with poor survival. Similar to EphA1, overexpression of EphA2 and ephrinA1 was more common in the early stage than in the late stage of cancer. On the other hand, reduced expression of ephrinA1 inhibits growth of HT29 colorectal cancer cells [103]. Recently, we reported that EphA3 expression positively correlated with tumour size, histological grade, depth of invasion, lymph node metastasis, distant metastasis and pTNM stage. In addition, patients with high expression of EphA3 had the lowest survival rate (P = 0.001) [104]. Therefore, EphA3 may play an important role in the progression of tumours, and appeared as one of the specific molecular markers for assessment of tumour biological behaviour and prognosis. Loss of EphB expression was correlated with colorectal cancer progression, suggesting that reduction of EphB activity could promote tumorigenesis [20]. Supporting this suggestion is the converse finding that highly elevated expression of EphB2 is associated with a longer survival time in colorectal cancer [20, 105, 106]. Reduced expression of the EphB2 gene, as well as high expression of EphA4 gene, has also been suggested to promote liver metastasis.
in colorectal cancer [107]. Overexpression of the EphA4 gene and reduced expression of the EphB2 gene may thus be a useful predictor of liver metastasis in patients with colorectal cancer. In addition, the overexpression of EphB3 enhanced cell-cell contacts and suppressed tumour growth in HT29 colorectal cancer [108]. Furthermore, EphB4 and ephrinB2 were highly expressed in colorectal cancer compared to the normal mucosa [109, 110]. This suggests that EphB4 and ephrinB2 may play a role in the progression of colorectal cancer.

Prostate cancer

A number of Eph receptors and ephrin ligands have been detected in prostate cancer. Walker-Daniels et al. [22] reported that EphA2 is overexpressed in human prostate cancer compared with benign prostate tissues, and overexpression of EphA2 has been linked with metastasis. EphA2 has also been shown to induce an inactive conformation of integrins and inhibit cell spreading, migration and integrin-mediated adhesion through rapid recruitment of the protein tyrosine phosphatase SHP2, and subsequent dephosphorylation and inactivation of FAK [49]. A recent experiment in prostate cancer tissue and cell lines showed that the frequency of EphA7 methylation was higher in cancer with higher Gleason scores [21]. In addition, ectopic expression of EphA7 in DU145 cells was able to inhibit cell colony formation, but not cell growth. As far as metastatic cancer is concerned, for example, Astin and colleagues [111] analysed the dynamics of prostate cancer cell lines co-cultured with fibroblasts, and demonstrated that the unimpeded migration of metastatic PC-3 cells towards fibroblasts was dependent on activation of EphB3 and EphB4 by ephrinB2.

Brain tumours

Eph receptors and ephrin ligands are involved in the development of the central nervous system [82–84, 112–114]. EphA2 overexpression in glioblastoma multiforme (GBM) has been indicated to be a critical mediator of invasiveness and thus also represents an attractive molecular target for the development of therapeutics against GBM [115]. Overexpression of EphA4 enhances cell proliferation and migration through promoting the FGFR1 signalling pathway [116]. EphA7 protein is also overexpressed in GBM, and is correlated with poor survival of GBM patients [117]. This may because of the fact that EphA7 could promote tumour neovascularization. Therefore, the local release of EphA7 inhibitors in to GBM could restrain tumour angiogenesis and improve patient outcome. Recent work demonstrated that EphA7 is an important mediator of neural progenitor apoptosis during brain development [118]. EphB2 expression is higher in glioblastomas, especially in invasive ones, than in low-grade astrocytomas or normal brain tissue [119]. EphB2 tyrosine phosphorylation can promote glioma migration and invasion, whereas blocking

| Cancer type   | Expression | Ephs/ephrins | References                                      |
|---------------|------------|--------------|------------------------------------------------|
| Breast cancer | Up         | EphA2, EphB4 | [16, 141, 142, 197–199]                         |
|               | Down       | –            |                                                 |
| Colorectal cancer | Up   | EphA1, EphA2, EphA3, EphA8, EphB4, ephrinA1, ephrinB2 | [5, 28, 104, 109, 110, 200, 201]                 |
|               | Down       | EphA6, EphA7, EphB1, EphB2 | [20]                                           |
| Prostate cancer | Up       | EphA2, EphA3, EphA5, EphA6, EphA7, EphA8, EphA10, EphB3, ephrinA2 | [202]                                          |
|               | Down       | –            |                                                 |
| Brain tumour, GBM | Up       | EphA2, EphA3, EphA4, EphA7, EphB2, EphB4, ephrinB3 | [19, 116, 117, 120, 189]                        |
|               | Down       | –            |                                                 |
| Melanoma      | Up         | EphA2, EphA3, EphB3, ephrinA1 | [10, 121, 125, 189, 203]                       |
|               | Down       | EphA4        | [204]                                          |
| Lung cancer   | Up         | EphA2, EphB3 | [23, 127]                                      |
|               | Down       | –            |                                                 |
| Hepatocellular cancer | Up | EphA3, ephrinA1 | [30, 129]                                      |
|               | Down       | –            |                                                 |
| Gastric cancer | Up         | EphA1, EphA2, EphA3, EphB2 | [24, 130, 131, 133, 135]                       |
|               | Down       | ephrinB1     | [25]                                           |
EphB2 could inhibit these aspects of tumorigenesis. Together, these data suggest that EphB2 has potential value for therapeutic intervention. Expression of ephrinB family members was determined in invading glioblastoma cells and glioma cell line U87, T98G, U251 and SNB19. EphrinB3 mRNA was up-regulated in all of these cells and promoted RAF1-dependent invasion of glioma cell lines [120]. Furthermore, ephrinB3 expression and phosphorylation were correlated with increasing human glioma grade.

**Melanoma**

Initial studies reported that some members of the Eph receptors family are abnormally expressed in melanoma cells compared with melanocytes. In addition, EphA2 expression was significantly higher in metastatic cells than in primary melanoma cells [121, 122]. EphA2 forward signalling in malignant melanoma can promote vasculogenic mimicry [123]. Moreover, Udayakumar et al. verified that EphA2 is an important oncogene in melanoma by analysing EphA2 levels in a panel of melanoma cell lines [124]. EphrinA1, a ligand of the EphA2 receptor, is not only a growth factor for melanoma cells [125] but is also angiogenic and a chemotactrant for endothelial cells. In addition, ephrinA1 was found to be expressed in 67% of metastatic melanomas, and 43% of advanced primary melanomas, but only in the occasional lesions [10]. Together, these studies suggest that ephrinA1 may play a role in promoting melanocytic cell growth and inducing vascularization in advanced melanomas.

**Lung cancer**

There are relatively few studies of Eph/ephrin family in lung cancer. EphA2 was found to be overexpressed in patients who subsequently developed brain metastases, whereas low expression of EphA2 was related to disease-free survival or contralateral lung metastasis [23]. The above data suggest that high levels of EphA2 could be used to identify the patients that are at risk of lung cancer metastasis to the brain. EphA2 mutations were demonstrated to be present in lung squamous cell carcinoma and were associated with increases in tumour invasion and survival. Whether or not EphA2 mutations could serve as a potential therapeutic target for lung squamous cell carcinoma requires further study [126]. In addition, Ji et al. [127] found that overexpression of EphB3 in NSCLC cell lines promoted cell growth and migration. Recently, this research group reported that they identified a novel EphB3-binding protein, the receptor for activated C-kinase 1 (RACK1). RACK1 regulates the assembly of signal complexes including protein phosphatase 2A, Akt and itself in response to EphB3 activation, resulting in inhibition of NSCLC metastasis [128].

**Hepatocellular cancer**

EphA3 was previously found to be expressed at higher level in hepatocellular carcinoma (HCC) than that in corresponding healthy tissue [129]. Remarkably, one novel missense mutation, a GAC to GTC transition (D219V) was found in the extracellular domain of EphA3, and two genetic alterations in the intracellular SAM domain of EphA3 appear to be polymorphisms [29]. In addition, the overexpression of ephrinA1 was more frequently detected in poorly differentiated HCC than in well differentiated HCC. This indicates that ephrinA1 may be associated with the malignant phenotype of HCC.

**Gastric cancer**

Wang et al. [130] found that EphA1 protein was significantly associated with depth of invasion and cancer stage. Furthermore, patients with EphA1 up-regulation had a shorter survival time than those with absence or downregulation of EphA1. EphA2 has been associated with malignant transformation and was positively correlated with tumour invasion, lymph node metastasis and TNM stage [24, 131]. Knockdown of EphA2 expression could inhibit gastric cancer cell proliferation and invasion in vitro and in vivo [132]. This indicates that the specific inhibition of EphA2 may be useful for gastric cancer therapy. More recently, we found that increased EphA3 expression was positively correlated with vascular endothelial growth factor (VEGF), microvessel density (MVD) and patient survival. Thus, EphA3 may play important roles in the angiogenesis and prognosis of gastric cancer. The combined detection of EphA3, VEGF and the determination of MVD, to some extent, can reflect the biological behaviour of gastric cancer and could be used to guide the choice of chemotherapy and molecular targeting therapy [133].

EphB2 mutations have been identified in human gastric tumours [134]. Reduced expression of EphB2 was significantly associated with advanced disease stage, poor histological differentiation and poor survival rate [135]. EphrinB1 are frequently overexpressed in gastric cancer, and the expression of ephrinB1 is especially high in poorly differentiated invasive tumour cells [25]. Accumulating evidence demonstrates that expression of B-type ephrins is closely associated with tumour cell invasion. Reduction of ephrinB1 expression inhibits migration and invasion of scirrhous gastric cancer cells in vitro without affecting tumour cell proliferation or apoptosis [136].

**Functions in tumour angiogenesis**

Angiogenesis, the formation and growth of new blood vessels by sprouting from existing vessels [137, 138], is critical for tumour growth and metastasis by supplying the tumour with nutrients, growth factors and oxygen [139]. Several Eph receptors and ephrins play an important role in tumour angiogenesis by mediating communication of vascular cells with other vascular cells, as well as tumour cells [140]. There is considerable evidence to support the tumour-promoting role of the Eph/ephrin family in angiogenesis [141].

Forward signalling induced by EphA2 is known to promote angiogenesis [142]. In vitro and in vivo experiments also found that EphA2 forward signalling increases vascular permeability though phosphorylation of claudins [143, 144]. Additional studies revealed the expression of both EphA2 and ephrinA1 in tumour cells of two xenograft
models from human breast cancer and Kaposi sarcoma, as well as in human cancer specimens [141]. A further study indicated that EphA2, which was positively correlated with VEGF expression, was overexpressed in squamous cell carcinoma of the tongue and was also implicated in angiogenesis [145]. EphB4 and its cognitive ligand ephrinB2 not only play an essential role in embryonic vessel development and vascular remodelling but also participate in tumour angiogenesis. It has been suggested that ephrinB2 promotes the vascular formation and remodelling in EphB4-positive tumour tissues [146]. In addition, Martiny-Baron et al. demonstrated that EphB4 forward signalling is an important mediator of VEGF-induced angiogenesis, because of that VEGF-induced angiogenesis could be inhibited by the inhibition of EphB4 forward signalling [147]. EphrinB2 reverse signalling is also required for VEGF-induced angiogenesis through regulation of VEGFR2 endocytosis [148].

Eph receptors and ephrin ligands as tumour therapeutics targets

Expression of Eph receptors and ephrin ligands are often up-regulated in various human malignant tumours. Decreases in Eph receptor levels can effectively suppress tumour growth in animal models. Therefore, Eph receptors and ephrin ligands represent probable new targets for anticancer therapies. To date, numerous strategies targeting Eph/ephrin family have been developed for cancer treatment, which we will elaborate below (Table 2).

Preventing receptor-ligand interactions

The activation of Eph receptors by ephrin ligands relies on direct contact between cells that express Ephs and ephrins to induce signalling. Preventing receptor-ligand interactions may be useful to inhibit Eph/ephrin function. A large number of molecules can be used for this purpose. As function-blocking antagonists, soluble Eph and ephrin exdomains that bind their corresponding partner can inhibit Eph/ephrin function during tumour progression and neovascularization [142, 149, 150]. Soluble EphA2-Fc can inhibit EphA forward signalling, but promote reverse signalling, whereas EphB4-Fc can inhibit both forward and reverse signalling. Both EphA2-Fc and EphB4-Fc can suppress tumour growth in mouse models by inhibiting tumour angiogenesis [150–154]. Furthermore, it was reported that soluble monomeric EphB4 significantly suppressed tumour growth in a mouse model [155, 156]. Seehnet et al. used the extracellular domain of EphB4 fused with human serum albumin to block ephrinB2 in Kaposi sarcoma cells in vitro. This block of ephrinB2 resulted in the inhibition of migration and invasion of Kaposi sarcoma cells in response to various growth factors [154]. Antagonistic antibodies (MAb 2H9) [157] and peptides (TNYL-RAW, SNEW, KYL, etc.) [158, 159] that compete with ephrins for binding to Eph receptors are also useful for blocking these interactions. Recently, Lambert et al. [160] have reported that KYL, APY and VTM antagonist peptides could selectively target EphA4 to inhibit ephrin binding to EphA4.

Two isomeric small molecules that selectively inhibit ephrin binding to EphA2 and EphA4 have been identified [161]. The peptides and small molecules could be used to develop pharmaceuticals that selectively targeting Eph receptors with high affinity. Agonistic antibodies have also been used to suppress tumour growth in mouse models. These agonists are activators of Eph-ephrin signalling that stimulate Eph forward signalling and could be used to negatively regulate tumour cell growth and to induce the degradation of Eph receptors in cancer cells [66, 162–164]. By stimulating its ephrinB2 ligand, EphB4 activates an anti-oncogenic pathway (Abi-Crk pathway) that can inhibit breast cancer cell survival, proliferation, motility and invasion [66]. Coffman et al. targeted EphA2 on cancer cells using agonistic antibodies that simulate the effect of ligand binding. They showed that agonistic EphA2 antibodies can decrease tumour growth in vivo through protein degradation [162]. Therefore, we suggest that Eph agonistic antibodies could be useful in cancer treatment in combination with chemotherapy. There are a great many approaches to identify inhibitors to the Eph kinase domain [147, 165–169]. For example, several 2,5-dimethylpyrrolyl benzoic acid derivatives are inhibitors of EphA4 receptors and 2,4-bis-anilinopyrimidines are inhibitors of EphB4 receptors. In addition, ALW II-49–7 was reported to inhibit EphB2 tyrosine kinase activity. Furthermore, NVP-BHG712, which was originally described as an inhibitor of EphB4 kinase, can inhibit VEGF-driven angiogenesis in vivo [147]. However, NVP-BHG712 can inhibit many kinases and is also non-selective for different Eph receptor kinases. Dasatinib is a small molecular inhibitor of multiple tyrosine kinases containing Src, BCR-ABL and c-Kit, multiple Eph kinases and platelet-derived growth factor-beta receptor kinases [170]. It is used to suppress proliferation of haematological malignancies [170, 171]. In addition, dasatinib can inhibit growth, migration and invasion of breast cancer cells [172]. Dasatinib can also inhibit invasion, and induce cell apoptosis of ovarian cancer, which was highly sensitive to dasatinib [173]. It was also reported that the potency of dasatinib may be because of an ability to decrease EphA2 phosphorylation [15]. Small interfering RNA (siRNA) that specifically induces destruction of specific mRNA is a powerful tool in the analysis of protein function and targeted therapeutics. Duxbury et al. demonstrated that EphA2 siRNA suppresses EphA2 expression, cellular invasiveness, anoikis resistance and FAK phosphorylation in vitro, and inhibited tumour growth and metastasis in a pancreatic cancer xenograft model [174]. In addition, knockdown of EphA2 inhibited endothelial expression of EphA2, suppressed ephrinA1- and VEGF-induced cell migration, inhibited cell proliferation and induced cell apoptosis in human glioma cells [175, 176]. It was demonstrated that targeted knockdown of EphB4 expression by siRNA (and antisense oligodeoxynucleotides (ODNs)) led to poor survival of breast cancer cells, and increased apoptosis [100]. Furthermore, antisense ODN-mediated EphB4 knockdown resulted in the suppression of tumour growth in a murine tumour xenograft model. Previous studies have indicated that siRNA targeting the oncoprotein EphA2 was incorporated into the neutral liposome 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) for efficient in vivo siRNA delivery [177]. Treatment with EphA2-targeting siRNA-DOPC resulted in significantly decreased tumour cell proliferation and tumour growth in an orthotopic mouse model of ovarian cancer [178].
**Table 2** Strategies targeting Eph receptors and ephrin ligands for cancer therapy.

| Treatment | Target | Tumour | References |
|-----------|--------|--------|------------|
| **Inhibitors of Eph/ephrin interaction** | | | |
| EphA2-FC, EphA3-FC | ephrinA | Breast cancer, Pancreatic cancer | [142, 149, 150] |
| EphB4-FC | EphB4 | Melanoma | [156] |
| Mab2H9 antagonistic antibody | EphB2 | Colorectal cancer | [157] |
| TNYL-RAW peptide | EphB4 | Breast cancer | [158] |
| SNEW peptide | EphB2 | Breast cancer | [158] |
| KYL, APY, VTM peptide | EphA4 | Angiogenesis | [159, 161] |
| 2,5-dimethylpyrroly benzoic acid derivatives | EphA4 | Angiogenesis | [161] |
| Disalicylic Acid-furanyl derivative | EphA2 | Prostate cancer | [205] |
| **Activators of Eph forward signalling** | | | |
| EA2,B233,3F2-WT antibody | EphA2 | Breast cancer | [162] |
| EA5 antibody | EphA2 | Ovarian cancer | [163] |
| mAB208 | EphA2 | Renal cell cancer | [164] |
| Dimerized IIIA4 antibody | EphA3 | Malignant Melanoma | [183] |
| YSA, SWL peptides | EphA2 | Breast cancer | [206] |
| **Kinase inhibitor** | | | |
| Dasatinib | EphA2 | Prostate cancer, Ovarian cancer, Pancreatic cancer | [15, 173, 207] |
| Benzenesulphonamide derivative | EphB4 | Angiogenesis | [165] |
| Xanthine derivatives | EphB4 | Hepatocellular cancer | [168] |
| **Inhibitor of Eph expression** | | | |
| EphA2 siRNA | EphA2 | Pancreatic cancer, Ovarian cancer | [174] [176, 177] |
| EphB4 siRNA | EphB4 | Breast cancer | [100] |
| Oligonucleotides | EphB4 | Breast cancer, Bladder cancer | [100, 208] |
| **Imaging agent** | | | |
| ⁶⁴Cu -DOTA-1C1 antibody | EphA2 | Colorectal cancer, Prostate cancer, Ovarian cancer, Glioblastoma, Malignant Melanoma | [182] |
| ¹¹¹Indium-labelled IIIA4 antibody | EphA3 | Malignant Melanoma | [183] |
Drug/toxin-conjugated antibody targeting of Eph-positive cancers

Monoclonal antibodies that selectively bind tumour cells provide a vehicle for targeted delivery of cytotoxins. A number of recent studies have provided insight into drug/toxin-conjugated Eph antibodies capable of killing tumour cells that express high levels of Eph receptors [157, 179, 180]. Organic compounds that are suitable for conjugation and delivery by antibodies have been identified. It has been described that auristatins, derivatives of the tubulin polymerization inhibitor, were used as potent cytotoxic agents delivered by conjugated antibodies [181]. Pseudomonas aeruginosa exotoxin A, which is a novel cytotoxin composed of ephrinA1 ligand conjugated to a bacterial toxin, was also used to kill GBM cells overexpressing EphA2 [13]. Jackson et al. demonstrated that the anti-EphA2 antibody-drug conjugate (1C1–maleimidocaproyl-MMAF (mcMMAF)) induces degradation of the EphA2 receptor and inhibits tumour growth in vivo [179]. In addition, an EphB2 antibody conjugated to monomethylauristatin E specifically killed EphB2-expressing colorectal cancer cells in vitro and in vivo [157]. However, EphB2 is also expressed in normal tissues, and the potential for this method to destroy normal cells needs to be further investigated. Therefore, advanced technology, drug potency and conjugation methods are urgently needed to develop safe and effective antibody-drug/toxin conjugates for the treatment of cancer.

Antibodies conjugated to imaging agents could be used for PET imaging. EphA2 labelled with 64Cu using the chelating agent 1,4,7,10-tetraazacyclododecane N,N',N'',N'''-tetraacetic acid (DOTA) was used for quantitative radioimmunoPET imaging of EphA2-expression tumour-bearing mice. The tumour uptake value of 64Cu-DOTA-1C1 obtained from PET imaging correlated very well with the tumour expression level of EphA2 in vivo [182]. In addition, both IIIA4 monoclonal antibodies and ephrinA5 that were labelled with 111Indium were successfully used for γ-camera imaging in solid tumour-bearing xenografts [183].

Targets for cancer immunotherapy

Dendritic cell-based tumour vaccines can induce protective antitumour immunity in tumour models, by inducing both the tumour-specific cytotoxic T-lymphocyte and helper-T cell response. There is some evidence that Eph receptors may be useful targets for cancer immunotherapy [14, 184–188]. A bispecific single-chain antibody (bscAb) that simultaneously targets EphA2 on tumour cells and the T cell receptor/CD3 complex on T cells can lyse EphA2-expressing tumour cells in vitro and in vivo [184]. In an experimental approach, EphA2-derived peptides that induce specific, tumour-reactive CD8+ or CD4+ T cell responses might be able to serve as agents for immunotherapy of renal cell carcinoma [185]. Yamaguchi et al. investigated the effectiveness of vaccination dendritic cells (DCs) loaded with EphA2-derived peptides (Eph-DCs) in a murine colon cancer model. They demonstrated that immunization with Eph-DCs suppressed MC38 tumour (with EphA2 overexpression) growth compared with the control group, and in contrast, Eph-DC vaccination had no influence on BL6 tumour (without EphA2 expression) growth [187]. Furthermore, a previous study showed that the synthetic EphA2883–891 peptide induces an antigen-specific cytotoxic T-lymphocyte response in human leucocyte antigen A2+ patient-derived peripheral blood mononuclear cells from EphA2-expression malignant gliomas [186]. EphA3- and EphB6-derived peptides were also suggested to be recognized by cancer-specific cytotoxic T cells [188, 189].

Conclusion

The Eph receptors that comprise the largest subgroup of tyrosine kinase, and their ephrin ligands, form a cell-cell system that is associated with various important biological processes, including nervous system development, angiogenesis and tumorigenesis. They regulate...
cell-to-cell adhesion, cell proliferation and viability, cytoskeletal organization and cell migration. Increasing experimental evidence indicates deregulated activation of Eph/ephrin signalling in cancer. Our understanding of the Eph/ephrin pathway has improved tremendously. Ephs/ephrins can influence tumour behaviour by bidirectional signalling as well as other signalling modalities. Every tumour cell has to integrate and translate the signals that it receives into corresponding cellular responses, to achieve its overall biological function. However, varying surface densities of Eph receptors and ephrin ligands on tumour cells may influence Eph receptor signalling and the cellular response. The binding characteristic formation of multimolecular, bidirectional signalling and cross-talk with other molecules and signalling pathways further contribute to the complexity of the Eph/ephrin system. Therefore, a detailed understanding of Eph/ephrin signalling is important to regulate Eph-mediated tumour cell responses, to exploit the tumour-specific expression of Eph receptors and ephrin ligands, and to provide potentially novel targets for anticancer therapies for Eph-expressing tumours.

To date, a number of strategies targeting the Eph/ephrin system have been developed for cancer treatment, such as the prevention of receptor-ligand interactions, targeted delivery of drugs and immunotherapy. However, the complexity of their signalling and biological functions complicates the development of effective therapeutic agents. Strategies targeting the Eph/ephrin system might be useful in tumours in which Eph receptors promote tumorigenesis, and ineffective or even detrimental in tumours in which Eph receptors suppress tumorigenesis. In addition, the side effects of Eph/ephrin-targeting agents on normal tissues expression these family members are not well documented. Further examination of changes in Eph/ephrin expression in tumours and cancer-related Eph/ephrin gene mutations, as well as the underlying molecular mechanisms of bidirectional signalling of the Eph/ephrin system are needed to develop successful, safe and effective therapeutic strategies.

Acknowledgements

This work was supported by the National Nature Science Foundation of China (no. 81172368), and the Committee of Science and Technology of Beijing, China (no. Z111107058811047). The funding bodies had no role in study design, data collection or analysis, decision to publish, or preparation of the manuscript.

Disclosures

The authors confirm that there are no conflicts of interest.

References

1. Wilkinson DG. Multiple roles of Eph receptors and ephrins in neural development. Nat Rev Neurosci. 2001; 2: 155–64.
2. Himanen JP, Nikolov DB. Eph receptors and ephrins. Int J Biochem Cell Biol. 2003; 35: 139–4.
3. Clifford N, Smith LM, Powell J, et al. The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. J Cell Biochem. 2008; 105: 1250–9.
4. Anon. Unified nomenclature for Eph family receptors and their ligands, the ephrins. Eph Nomenclature Committee. Cell. 1997; 90: 403–4.
5. Hirai H, Maru Y, Hagiwara K, et al. A novel putative tyrosine kinase receptor encoded by the eph gene. Science. 1987; 238: 1717–20.
6. Bartley TD, Hunt RW, Welcher AA, et al. B61 is a ligand for the ECK receptor protein-tyrosine kinase. Nature. 1994; 368: 558–60.
7. Beckmann MP, Cerretti DP, Baum P, et al. Molecular characterization of a family of ligands for eph-related tyrosine kinase receptors. EMBO J. 1994; 13: 3757–62.
8. Palmer A, Klein R. Multiple roles of ephrins in morphogenesis, neuronal networking, and brain function. Genes Dev. 2003; 17: 1429–50.
9. Hafner C, Becker B, Landthaler M, et al. Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer. Mod Pathol. 2006; 19: 1369–77.
10. Easty DJ, Hill SP, Hsu MY, et al. Up-regulation of ephrin-A1 during melanoma progression. Int J Cancer. 1999; 84: 494–501.
11. Vogt T, Stolz W, Welch J, et al. Overexpression of Lerk-S/EphS5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res. 1998; 4: 791–7.
12. Tang XX, Zhao H, Robinson ME, et al. Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A. 2000; 97: 10936–41.
13. Wykosky J, Gibe DM, Debinski W. A novel, potent, and specific ephrinA1-based cytoxin against EphA2 receptor expressing tumor cells. Mol Cancer Ther. 2007; 6: 3208–18.
14. Hatano M, Eguchi J, Tatsumi T, et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia. 2005; 7: 717–22.
15. Chang Q, Jorgensen C, Pawson T, et al. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer. 2008; 99: 1074–82.
16. Zeilinski DP, Zantek ND, Stewart JC, et al. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res. 2001; 61: 2301–8.
17. Fox BP, Kandpal RP. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem Biophys Res Commun. 2004; 318: 882–92.
18. Bercia G, Flutsch B, Altermatt HJ, et al. Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast. Oncol Rep. 2002; 9: 985–9.
19. Hafner C, Schmitz G, Meyer S, et al. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem. 2004; 50: 490–9.
20. Battile E, Bacani J, Begthel H, et al. EphB receptor activity suppresses colorectal cancer progression. Nature. 2005; 435: 1126–30.
21. Guan M, Xu C, Zhang F, et al. Aberrant methylation of EphA2 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 2009; 124: 88–94.
22. Walker-Daniels J, Coffman K, Azimi M, et al. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate. 1999; 41: 275–80.

23. Kinch MS, Moore MB, Hargole DH Jr. Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res. 2003; 9: 613–8.

24. Nakamura R, Kataoka H, Sato N, et al. EphA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005; 96: 42–7.

25. Kataoka H, Tanaka M, Kanamori M, et al. Expression profile of EFN B1, EFN B2, two ligands of EphB2 in human gastric cancer. J Cancer Res Clin Oncol. 2002; 128: 343–8.

26. Landen CN, Kinch MS, Sood AK. EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets. 2005; 9: 1179–87.

27. Herath NI, Spanevello MD, Sabesan S, et al. Over-expression of Eph and ephrin genes in advanced ovarian cancer: ephrin gene expression correlates with shortened survival. BMC Cancer. 2006; 6: 144.

28. Miyazaki T, Kato H, Fukuchi M, et al. EphA2 overexpression correlates with poor prognosis in esophageal squamous cell carcinoma. Int J Cancer. 2003; 103: 657–63.

29. Bae HJ, Song JH, Noh JH, et al. Low frequency mutation of the Eph receptor A3 gene in hepatocellular carcinoma. Neoplasma. 2009; 56: 331–4.

30. Iida H, Honda M, Kawai HF, et al. Ephrin-A1 expression contributes to the malignant characteristics of (alpha)-fetoprotein producing hepatocellular carcinoma. Gut. 2005; 54: 843–51.

31. Karidis NP, Giaginis C, Tsourouflis G, et al. Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: an immunohistochemical study. Med Sci Monit. 2011; 17: BR257–65.

32. Kiyokawa E, Takai S, Tanaka M, et al. Overexpression of ERK, an Eph family receptor protein tyrosine kinase, in various human tumors. Cancer Res. 1994; 54: 345–50.

33. Bruckner P, Pablo Labrador J, Scheiffele P, et al. EphrinB ligands recruit GRIP family PDZ adaptor proteins into raft membrane microdomains. Neuron. 1999; 22: 511–24.

34. Torres R, Firestein BL, Dong H, et al. PDZ proteins bind, cluster, and synaptically colocalize with Eph receptors and their ephrin ligands. Neuron. 1998; 21: 1453–63.

35. Kullander K, Klein R. Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol. 2002; 3: 475–86.

36. Himanen JP, Chumley MJ, Lackmann M, et al. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat Neurosci. 2004; 7: 501–9.

37. Gale NW, Holland SJ, Valenzuela DM, et al. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron. 1996; 17: 9–19.

38. Kalo MS, Pasquale EB. Multiple in vivo ephrin phosphorylation sites in EphB receptors. Biochemistry. 1998; 31: 31496–508.

39. Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends Cell Biol. 2007; 17: 230–8.

40. Yin Y, Yamashita Y, Noda H, et al. Eph receptor tyrosine kinases interact with co-expressed ephrin-A ligands in cis. Neurorob Res. 2004; 47: 295–106.

41. Carvalho RF, Beutler M, Marler KV, et al. Silencing of EphA3 through a cis interaction with ephrinA5. Nat Neurosci. 2006; 9: 322–30.

42. Himanen JP, Nikolov DB. Eph signalling: a structural view. Trends Cell Biol. 2003; 13: 467–511.

43. Boyd AW, Lackmann M. Signals from Eph and ephrin proteins: a developmental tool kit. Sci STKE. 2001; 1: 6–.

44. Matsuoka H, Obama H, Kelly ML, et al. Biphagic functions of the kinase-defective Eph6 receptor in cell adhesion and migration. J Biol Chem. 2005; 280: 29355–63.

45. Gu C, Shim S, Shin J, et al. The EphA8 receptor induces sustained MAP kinase activation to promote neurite outgrowth in neuronal cells. Oncogene. 2005; 24: 4243–56.

46. Gu C, Park S. The EphA8 receptor regulates integrin activity through p110gamma phosphatidylinositol-3 kinase in a tyrosine kinase activity-independent manner. Mol Cell Biol. 2001; 21: 4579–97.

47. Noren NK, Yang Y, Sildorff M, et al. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Biochem J. 2004; 37: 433–42.

48. Pasquale EB. Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol. 2005; 6: 462–75.

49. Miao H, Wei BR, Peshl DM, et al. Activation of EphA receptor tyrosine kinase inhibits the Ras/MEK/MAPK pathway. Nat Cell Biol. 2001; 3: 527–30.

50. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001; 410: 37–40.

51. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediate ERK, JNK, and p38 protein kinases. Science. 2002: 298: 1911–2.

52. Elowe S, Holland SJ, Kulkarni S, et al. Downregulation of the Ras-mitogen-activated protein kinase pathway by the EphB2 receptor tyrosine kinase is required for ephrin-induced neurite retraction. Mol Cell Biol. 2001; 21: 7429–41.

53. Pratt RL, Kinch MS. Activation of the EphA2 tyrosine kinase stimulates the MAP/ERK kinase signaling cascade. Oncogene. 2002; 21: 7690–9.

54. Zisch AH, Pazzaglia C, Freeman AL, et al. Replacing two conserved tyrosines of the EphB2 receptor with glutamic acid prevents binding of SH2 domains without abrogating kinase activity and biological responses. Oncogene. 2000; 19: 177–87.

55. Tong J, Elowe S, Nash P, et al. Manipulation of EphB2 regulatory motifs and SH2
binding sites switches MAPK signaling and biological activity. J Biol Chem. 2003; 278: 6111–9.
64. Genander M, Halford MM, Xu NJ, et al. Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell. 2009; 139: 679–92.
65. Holmberg J, Genander M, Halford MM, et al. EphB receptors coordinate migration and proliferation in the intestinal stem cell niche. Cell 2006; 125: 1151–63.
66. Noren NK, Foos G, Hauser CA, et al. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abi-Crk pathway. Nat Cell Biol. 2006; 8: 815–25.
67. Bruckner K, Pasquale EB, Klein R. Tyrosine phosphorylation of transmembrane ligands for Eph receptors. Science. 1997; 275: 1640–3.
68. Davy A, Gale NW, Murray EW, et al. Compartmentalized signaling by GPI-anchored ephrin-A5 requires the Fyn tyrosine kinase to regulate cellular adhesion. Genes Dev. 1999; 13: 3125–35.
69. Bonanomi D, Chivatakarn O, Bai G, et al. Ret is a multifunctional coreceptor that integrates diffusible and contact-axon guidance signals. Cell 2012; 148: 568–82.
70. Oh P, Schnitzer JE. Segregation of heterotrimeric G proteins in cell surface microdomains. G(q) binds caveolin to concentrate in caveolae, whereas G(i) and G(s) target lipid rafts by default. Mol Biol Cell. 2001; 12: 685–98.
71. Stefanova I, Horejsi V, Anostegui IJ, et al. GPI-anchored cell-surface molecules complexed to protein tyrosine kinases. Science. 1991; 254: 1016–9.
72. Murray EW, Robbins SM. Antibody cross-linking of the glycosylphosphatidylinositol-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement. J Biol Chem. 1998; 273: 25279–84.
73. Huai J, Drescher U. An ephrin-A-dependent signaling pathway controls integrin function and is linked to the tyrosine phosphorylation of a 120-kDa protein. J Biol Chem. 2001; 276: 6689–94.
74. Davy A, Robbins SM. Ephrin-A5 modulates cell adhesion and morphology in an integrin-dependent manner. EMBO J. 2000; 19: 5396–405.
75. Holland SJ, Gale NW, Mbamalu G, et al. Bidirectional signalling through the Eph-family receptor Nuk and its transmembrane ligands. Nature. 1996; 383: 722–5.
76. Arvanitis D, Davy A. Eph/ephrin signaling: networks. Genes Dev. 2008; 22: 416–29.
77. Cowan CA, Henkemeyer M. The SH2/SH3 adaptor Grb4 transduces B-ephrin reverse signals. Nature. 2001; 413: 174–9.
78. Lu Q, Sun EE, Klein RS, et al. Ephrin-B reverse signaling is mediated by a novel PDZ-RGS protein and selectively inhibits G protein-coupled chemoatraction. Cell. 2001; 105: 69–79.
79. Xu Q, Mellitzer G, Robinson V, et al. In vivo cell sorting in complementary segmental domains mediated by Eph receptors and ephrins. Nature. 1999; 399: 267–71.
80. Adams RH, Diella F, Hennig S, et al. The cytoplasmic domain of the ligand ephrinB2 is required for vascular morphogenesis but not cranial neural crest migration. Cell. 2001; 104: 57–69.
81. Huynh-Do U, Vindis C, Liu H, et al. Ephrin-B1 transduces signals to activate integrin-mediated migration, attachment and angiogenesis. J Cell Sci. 2002; 115: 3073–81.
82. Tessier-Lavigne M. Eph receptor tyrosine kinases, axon repulsion, and the development of topographic maps. Cell. 1995; 82: 345–8.
83. Winslow JW, Moran P, Valverde J, et al. Cloning of AL-1, a ligand for an Eph-related tyrosine kinase receptor involved in axon bundle formation. Neuron. 1995; 14: 973–81.
84. Wang HU, Anderson DJ. Eph family transmembrane ligands can mediate repulsive guidance of trunk neural crest migration and motor axon outgrowth. Neuron. 1997; 18: 383–96.
85. Daiba MB, Takasu MA, Lin NZ, et al. EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell. 2000; 103: 945–56.
86. Ethell IM, Irie F, Kalo MS, et al. EphB/syndecan-2 signaling in dendritic spine morphogenesis. Neuron. 2001; 31: 1001–13.
87. Battle E, Henderson JT, Beghtel H, et al. Beta-catenin and TGF mediate cell positioning in the intestinal epithelium by controlling the expression of EphB/ephrinB. Cell. 2002; 111: 251–63.
88. Frisen J, Holmberg J, Barbadic M. Ephrins and their Eph receptors: multitaled directors of embryonic development. EMBO J. 1999; 18: 5159–65.
89. Herath NI, Boyd AW. The role of Eph receptors and ephrin ligands in colorectal cancer. Int J Cancer. 2010; 126: 203–11.
90. Adams RH. Vascular patterning by Eph receptor tyrosine kinases and ephrins. Semin Cell Dev Biol. 2002; 13: 55–60.
91. Ogawa K, Wada H, Okada N, et al. EphB2 and ephrin-B1 expressed in the adult kidney regulate the cytoarchitecture of medullary tubule cells through Rho family GTPases. J Cell Sci. 2006; 119: 559–70.
92. Gerlai R. Eph receptors and neural plasticity. Nat Rev Neurosci. 2001; 2: 205–9.
93. Brantly-Sieders D, Schmidt S, Parker M, et al. Eph receptor tyrosine kinases in tumor and tumor microenvironment. Curr Pharm Des. 2004; 10: 3431–42.
94. Walker-Daniels J, Hess AR, Hendrix MJ, et al. Differential regulation of EphA2 in normal and malignant cells. Am J Pathol. 2003; 162: 1037–42.
95. Brantly-Sieders DM, Fang WB, Hicks DJ, et al. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J. 2005; 19: 1884–6.
96. Fang WB, Brantly-Sieders DM, Parker MA, et al. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene. 2005; 24: 7859–68.
97. Brantly-Sieders DM, Zhuang G, Hicks D, et al. The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest. 2008; 118: 64–78.
98. Larsen AB, Pedersen NW, Stockhausen MT, et al. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor–induced cancer cell motility. Mol Cancer Res. 2007; 5: 283–93.
99. Foveau B, Boulay G, Pinte S, et al. The receptor tyrosine kinase EphA2 is a direct target gene of hypermethylated in cancer 1 (HIC1). J Biol Chem. 2012; 287: 5366–78.
100. Kumar SR, Singh J, Xia G, et al. Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006; 169: 279–93.
101. Brantly-Sieders DM, Jiang A, Sarma K, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE. 2011; 6: 1–9.
102. Herath NI, Doecke J, Spanevello MD, et al. Epigenetic silencing of EphA1 expression in colorectal cancer is correlated with poor survival. Br J Cancer. 2009; 100: 1095–102.
103. Potla L, Boghaert ER, Armellino D, et al. Reduced expression of EphrinA1 (EFNA1) inhibits three-dimensional growth of HT29 colon carcinoma cells. Cancer Lett. 2002; 175: 187–95.
104. Xi QH, Zhao P. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. J Clin Pathol. 2011; 64: 498–503.
Astin JW, Batson J, Kadir S, Stephenson SA, Slomka S, Douglas EL, Wykosky J, Gibo DM, Stanton C, Wang LF, Fokas E, Juricko J, Depaepe V, Suarez-Gonzalez N, Dufour A, et al. Ephrin signalling controls brain size by regulating apoptosis of neural progenitors. Nature. 2005; 435: 1244–50.

Nakada M, Niska JA, Miyamori H, et al. The phosphorylation of EphB2 receptor regulates migration and invasion of human glioma cells. Cancer Res. 2004; 64: 3179–85.

Nakada M, Drake KL, Nakada S, et al. Ephrin-B3 ligand promotes glioma invasion through activation of Rac1. Cancer Res. 2006; 66: 6942–500.

Kinch MS, Carles-Kinch K. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin Exp Metastasis. 2003; 20: 59–68.

Hendrix MJ, Settor EA, Hess AR, et al. Molecular plasticity of human melanoma cells. Oncogene. 2003; 22: 3070-5.

Hess AR, Settor EA, Gruman LM, et al. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Ther. 2006; 5: 228–33.

Udayakumar D, Zhang G, Ji Z, et al. EphA2 is a critical oncogene in melanoma. Oncogene. 2011; 30: 4921–9.

Easty DJ, Hertyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis. Int J Cancer. 1996; 50: 239–46.

Faoro L, Singleton PA, Cervantes GM, et al. EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem. 2010; 285: 18575–85.

Ji XD, Li G, Feng YX, et al. EphB3 is over-expressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res. 2011; 71: 1156–66.

Li G, Ji XD, Gao H, et al. EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat Commun. 2012; 3: 1–10.

Nam SW, Park JY, Ramasamy A, et al. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology. 2005; 42: 809–18.

Wang J, Dong Y, Wang X, et al. Expression of EphA1 in gastric carcinomas is associated with metastasis and survival. Oncol Rep. 2010; 24: 1577–84.

Yuan W, Chen Z, Wu S, et al. Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res. 2009; 15: 473–8.

Yuan W, Chen Z, Wu S, et al. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma. 2012; 59: 105–13.

Xu HQ, Wu XS, Wei B, et al. Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival. J Gastroenterol. 2012; 47: 785–94.

Davalos V, Dopeso H, Velho S, et al. High EphB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene. 2007; 26: 308–11.

Yu G, Gao Y, Ni C, et al. Reduced expression of EphB2 is significantly associated with nodal metastasis in Chinese patients with gastric cancer. J Cancer Res Clin Oncol. 2011; 137: 73–80.

Tanaka M, Kamata R, Takigahira M, et al. Phosphorylation of ephrin-B1 regulates dissemination of gastric scirrhous carcinoma. Am J Pathol. 2007; 171: 68–78.

Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86: 353–64.

Iruela-Arispe ML, Dvorak HF. Angiogenesis: a dynamic balance of stimulators and inhibitors. Thromb Haemost. 1997; 78: 672–7.

Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1999; 91: 4–6.

Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010; 10: 165–80.

Ogawa K, Pasqualini R, Lindberg RA, et al. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene. 2000; 19: 6043–52.

Brantley DM, Cheng N, Thompson EJ, et al. Soluble Eph A receptors inhibit human tumor angiogenesis and progression in vivo. Oncogene. 2002; 21: 7011–26.

Miao H, Wang B. Eph/ephrin signalling in epithelial development and homeostasis. Int J Biochem Cell Biol. 2009; 41: 762–70.

Larson J, Schomberg S, Schroeder W, et al. Endothelial EphA receptor stimulation increases lung vascular permeability. Am J Physiol Lung Cell Mol Physiol. 2008; 295: L431–9.

Shao Z, Zhang WF, Chen XM, et al. Expression of EphA2 and VEGF in squamous cell carcinoma of the tongue: correlation with the angiogenesis and clinical outcome. Oral Oncol. 2008; 44: 1110–7.

Noren NK, Lu M, Freeman AL, et al. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci USA. 2004; 101: 5583–8.

Martiny-Baron G, Holzer P, Billy E, et al. The small molecule specific EphB4 kinase inhibitor...
NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010, 13: 259–67.

Sawamiphak S, Seidel S, Essmann CL, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010; 465: 487–91.

Cheng N, Brantley D, Fang WB, et al. Inhibition of VEGF-dependent multistage carcino genesis by soluble EphA receptors. Neoplasia. 2003; 5: 445–56.

Dobrzanski P, Hunter K, Jones-Bolin S, et al. Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist. Cancer Res. 2004; 64: 910–9.

Ireton RC, Chen J. EphA2 receptor tyrosine kinase as a promising target for cancer therapeutics. Curr Cancer Drug Targets. 2005; 5: 149–57.

Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res. 2008; 6: 1795–806.

Kuijper S, Turner CJ, Adams RH. Regulation of angiogenesis by Eph-ephrin interactions. Trends Cardiovasc Med. 2007; 17: 145–51.

Schehnert JS, Ley EJ, Krasnoperov V, et al. The role of Ephs, Ephins, and growth factors in Kaposi sarcoma and implications of Eph-B2 blockade. Blood. 2009; 113: 254–63.

Kertesz N, Krasnoperov V, Reddy R, et al. The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth. Blood. 2006; 107: 2330–8.

Martiny-Baron G, Kortt T, Schaffner F, et al. Inhibition of tumor growth and angiogenesis by soluble EphB4. Neoplasia. 2004; 6: 248–57.

Mao W, Luis E, Ross S, et al. EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer. Cancer Res. 2004; 64: 781–8.

Koolpe M, Burgess R, Dail M, et al. EphB receptor-binding peptides identified by phage display enable design of an antagonist with ephrin-like affinity. J Biol Chem. 2005; 280: 17301–11.

Murai KK, Nguyen LN, Koolpe M, et al. Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol Cell Neurosci. 2003; 24: 1000–11.

Lamberto I, Qin H, Noberini R, et al. Distinctive binding of three angiogenic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J. 2012; 445: 47–56.

Noberini R, Koolpe M, Peddibhola S, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphB2 receptors. J Biol Chem. 2008; 283: 29461–72.

Coffman KT, Hu M, Carles-Kinch K, et al. Differential EphA2 epitope display on normal versus malignant cells. Cancer Res. 2003; 63: 7907–12.

Landen CN Jr, Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006; 98: 1558–70.

Wesa AK, Herrem CJ, Mandic M, et al. Enhancement of specific CD8+ T cell recognition of EphA2 tumors in vitro and in vivo after treatment with ligand agonists. J Immunol. 2008; 181: 7721–7.

Miyazaki Y, Nakano M, Sato H, et al. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno-furo-[3,2-c:2]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenic kinases. Bioorg Med Chem Lett. 2007; 17: 250–4.

Bardelle C, Coleman T, Cross D, et al. Inhibitors of the tyrosine kinase EphB4. Part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. Bioorg Med Chem Lett. 2008; 18: 5717–21.

Choi Y, Syeda F, Walker JR, et al. Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009; 19: 4467–70.

Laffleur K, Huang D, Zhou T, et al. Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009: 52: 6433–46.

Qiao L, Choi S, Case A, et al. Structure–activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009; 19: 6122–6.

Keam SJ. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs. 2008; 22: 59–69.

Buehler R, Mesa T, Vuitur A, et al. Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res. 2008; 6: 1766–74.

Pichot CS, Hartig SM, Xia L, et al. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer. 2009: 101: 38–47.

Konecny GE, Glas R, Dering J, et al. Activity of the multikine inhibitor dasatinib against ovarian cancer cells. Br J Cancer. 2009; 101: 1699–708.

Duxbury MS, Ito H, Zinner MJ, et al. EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene. 2004; 23: 1448–56.

Cheng N, Branfley DM, Liu H, et al. Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res. 2002; 1: 2–11.

Zhou Z, Yuan X, Li Z, et al. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg Neurol. 2008; 70: 562–8; discussion 8–9.

Landen CN Jr, Chavez-Reyes A, Bucana C, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005; 65: 6910–8.

Shahzad MM, Lu C, Lee JW, et al. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009; 8: 1027–34.

Jackson D, Gooya J, Mao S, et al. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo. Cancer Res. 2008; 68: 9367–74.

Lee JW, Han HD, Shahzad MM, et al. EphA2 immunocjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009; 101: 1193–205.

Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody australin conjugates for cancer therapy. Nat Biotechnol. 2003; 21: 778–84.

Cai W, Ebrahimnejad A, Chen K, et al. Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging. 2007; 34: 2024–36.

Vearing C, Lee FT, Wimmer-Kleikamp S, et al. Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumour-targeting reagents. Cancer Res. 2006; 65: 6745–54.

Hammond SA, Lutterbuese R, Roff S, et al. Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct. Cancer Res. 2007; 67: 3927–35.

Tatsumi T, Herrem CJ, Olson WC, et al. Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res. 2003; 63: 4481–9.

Alves PM, Faure D, Graff-Dubois S, et al. EphA2 as target of anticancer immunother-
apy; identification of HLA-A*0201-restricted epitopes. Cancer Res. 2003; 63: 8476–80.
187. Yamaguchi S, Tatsumi T, Takehara T, et al. Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer. 2007; 110: 1469–77.
188. Jin M, Komohara Y, Shichijo S, et al. Erythropoietin-producing hepatocyte B6 variant-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A2+ glioma patients. Cancer Sci 2008; 99: 1656–62.
189. Chiar R, Hanes G, Stroobant V, et al. Identification of a tumor-specific shared antigen derived from an Eph receptor and presented to CD4 T cells on HLA class II molecules. Cancer Res 2000; 60: 4855–63.
190. Miao H, Li DQ, Mukherjee A, et al. EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell. 2009; 16: 9–20.
191. Menges CW, McCance DJ. Constitutive activation of the Raf-MAK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor. Oncogene 2008; 27: 2934–40.
192. Parri M, Teddei ML, Bianchini F, et al. EphA2 reexpression prompts invasion of melanoma cells shifting from mesenchymal to amoeboid-like motility style. Cancer Res. 2009; 69: 2072–81.
193. Klein R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci. 2009; 12: 15–20.
194. Yamazaki T, Masuda J, Omori T, et al. EphA1 interacts with integrin-linked kinase and regulates cell morphology and motility. J Cell Sci. 2009; 122: 243–55.
195. Henkemeyer M, Itkis OS, Ngo M, et al. Multiple Eph receptor tyrosine kinases shape dendritic spines in the hippocampus. J Cell Biol. 2003; 163: 1313–26.
196. Dail M, Richter M, Godement P, et al. Eph receptors inactivate R-Ras through different mechanisms to achieve cell repulsion. J Cell Sci. 2006; 119: 1244–54.
197. Kourou-Mehr H, Werb Z. Candidate regulators of mammary branching morphogenesis identified by genome-wide transcript analysis. Dev Dyn. 2006; 235: 3404–12.
198. Pan M. Overexpression of EphA2 gene in invasive human breast cancer and its association with hormone receptor status [ASCO Annual Meeting Proceedings]. J Clin Oncol. 2005; 23: 9583.
199. Wu Q, Suo Z, Risberg B, et al. Expression of EphA2 and EphB4 in breast carcinoma. Pathol Oncol Res. 2004; 10: 26–33.
200. Maru Y, Hirai H, Takaku F. Overexpression confers an oncogenic potential upon the eph gene. Oncogene. 1990; 5: 445–7.
201. Kataoka H, Igarashi H, Kanamori M, et al. Correlation of EphA2 overexpression with high microvessel count in human primary colorectal cancer. Cancer Sci. 2004; 95: 136–41.
202. Fox BP, Tabone CJ, Kandpal RP. Potential clinical relevance of Eph receptors and ephrin ligands expressed in prostate carcinoma cell lines. Biochem Biophys Res Commun. 2008; 342: 1263–72.
203. Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000; 19: 5614–9.
204. Easty DJ, Mitchell PJ, Patel K, et al. Loss of expression of receptor tyrosine kinase family genes PTK7 and SEK in metastatic melanoma. Int J Cancer. 1997; 71: 1061–5.
205. Noberini R, De SK, Zhang Z, et al. A disaccharide furanyl derivative inhibits ephrin binding to a subset of eph receptors. Chem Biol Drug Des. 2011; 78: 667–78.
206. Koolpe M, Dail M, Pasquale EB. An ephrin mimetic peptide that selectively targets the EphA2 receptor. J Biol Chem. 2002; 277: 46974–9.
207. Wang XD, Reeves K, Luo FR, et al. Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol. 2007; 8: R255. doi:10.1186/gb-2007-8-11-r255.
208. Xia G, Kumar SR, Stein JP, et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2006; 25: 769–80.